Balyasny Asset Management
MLTX icon

Balyasny Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Balyasny Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,700
Closed -$213K – 3381
2025
Q3 		$213K Buy
+29,700
New +$1.55M ﹤0.01% 2708

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's MLTX Position: Q1 2026 in Review

Balyasny Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 32% in Q1 2026, selling an estimated $8.37M and leaving 1,065,610 shares worth $19.9M. The position accounts for 0.03% of the portfolio, ranked #694.

Balyasny Asset Management first reported a position in MLTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $36.1M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Balyasny Asset Management held 1,065,610 shares of MoonLake Immunotherapeutics worth $19.9M as of Q1 2026.
  • Balyasny Asset Management sold 505,461 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $8.37M.
  • MoonLake Immunotherapeutics made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #694 holding.
  • Balyasny Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2022 and has held it in 15 quarters since.
  • Balyasny Asset Management's MoonLake Immunotherapeutics position peaked at $36.1M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.